Washout periods for brimonidine 0.2% and latanoprost 0.005%

被引:50
|
作者
Stewart, WC
Holmes, KT
Johnson, MA
机构
[1] Pharmaceut Res Corp, Charleston, SC 29412 USA
[2] Univ S Carolina, Sch Med, Carolina Eye Inst, Columbia, SC USA
[3] Atlanta Res Co LLC, Atlanta, GA USA
关键词
D O I
10.1016/S0002-9394(00)00930-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the intraocular pressure washout time after discontinuing brimonidine 0.2% twice daily and latanoprost 0.005% once every evening. METHODS: We discontinued brimonidine or latanoprost in a masked fashion from primary open-angle glaucoma or ocular hypertensive patients. The intraocular pressure was measured twice weekly until patients returned to untreated baseline. RESULTS: In 32 patients, the mean longest eye washout time for brimonidine (n = 15) was 3.3 +/- 3.0 weeks and for latanoprost (n = 17) was 4.4 +/- 3.2 weeks (P = .24) In all but one patient, brimonidine returned to baseline by 5 weeks and latanoprost returned by 8 weeks. CONCLUSION: After discontinuing latanoprost or brimonidine, a wide variation exists in washout times among individuals, with latanoprost demonstrating a trend to a longer washout period, (Am J Ophthalmol 2001;131: 798-799. (C) 2001 by Elsevier Science Inc. All rights reserved.).
引用
收藏
页码:798 / 799
页数:2
相关论文
共 50 条
  • [31] A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study
    Tau, Julia
    Silvia Passerini, Maria
    del Papa, Melina
    Aguilar, Alejandro
    Berra, Alejandro
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (06) : 1941 - 1946
  • [32] Latanoprost 0.005%: evaluation of its effect on accommodative capacity
    Troiano, P
    Oldani, A
    Gozzini, C
    Iraci, M
    Dalpozzo, R
    Baratta, M
    De Mattia, M
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2000, 78 : 52 - 54
  • [33] The influence of Latanoprost 0.005% on the pupil reaction in human eyes
    Dinslage, S
    Diestelhorst, M
    Kühner, H
    Krieglstein, GK
    OPHTHALMOLOGE, 2000, 97 (06): : 396 - 401
  • [34] A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study
    Julia Tau
    María Silvia Passerini
    Melina del Papa
    Alejandro Aguilar
    Alejandro Berra
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1941 - 1946
  • [35] Clinical experience with latanoprost 0.005% in a predominantly black population
    Jones, LS
    Kosoko, O
    Copeland, RA
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1999, 40 (04) : S832 - S832
  • [36] COMPARISON OF TOPICAL LA- TANOPROST 0.005 % AND BRIMONIDINE 0.2% EYE DROPS IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH OPEN ANGLE GLAUCOMA
    T.Simsek
    A.Batman
    U.Elgin
    M.Alper
    O.Zilelioglu
    国际眼科杂志, 2003, (01) : 75 - 75
  • [37] Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature
    Konieczka, Katarzyna
    Koch, Simone
    Hauenstein, Daniela
    Chackathayil, Thomas Navin
    Binggeli, Tatjana
    Schoetzau, Andreas
    Flammer, Josef
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2019, 8 (03):
  • [38] A comparison of efficacy, safety, and quality of life of brimonidine with latanoprost vs latanoprost with timolol.
    Walters, TR
    Shapiro, AM
    Chapin, MJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S514 - S514
  • [40] REPEATABILITY TO 0.2 MILLIONTH - (0.005 MIKRON)
    MOORE, WR
    MICROTECNIC, 1967, 21 (01): : 62 - &